Expression, proliferation activity and clinical significance of cathepsin B and cathepsin L in operated lung cancer

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2767-2772

  Kayser, Klaus ^a   Richter, Natalia ^a   Hufnagl, Peter ^a   Kayser, Gian ^b   Kos, Janko ^c   Werle, Bernd ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c JO EF STEFAN INSTITUTE   (Slovenia)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cathepsin B; Cathepsin L; Ki 67; Lung cancer; Syntactic structure analysis

Indexed keywords

CATHEPSIN B; CATHEPSIN L; PARAFFIN; TUMOR MARKER;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CATHEPSIN B; CATHEPSINS; CELL DIVISION; CYSTEINE ENDOPEPTIDASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MACROPHAGES; MALE; MESOTHELIOMA; NEOPLASM STAGING; SURVIVAL RATE;

EID: 0043125549     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kayser K: Analytical Lung Pathology, Heidelberg, New York, Springer, 1992.
2. Higashiyama M, Doi O, Kodama K, Yokouchi H and Tateishi R: The prognostic implications of cathepsin B expression in pulmonary adenocarcinomas. An immunohistochemical study. Jpn J Cancer Clin 37: 11151-1157, 1991.
3. Heidtmann HH, Salge U, Havemann K, Kirschke H and Wiederanders B: Secretion of a latent, acid activatable cathepsin L precursor by human non-small cell lung cancer cell lines. Oncol Res 5: 4414-51, 1993.
4. Inoue T, Ishida T, Sugio K and Sugimachi K: Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res 54: 6133-6136, 1994.
5. Krepela E, Prochazka J, Mynarikova H, Karova B, Polak J, Cermak J and Roubkova H: Multiple forms of cathepsin B in human lung cancer. Int J Cancer 61: 44-53, 1995.
6. Ledakis P, Tester WT, Rosenberg N, Romero-Fischmann D, Daskal I and Lah TT: Cathepsins D, B, and L in malignant human lung tissue. Clin Cancer Res 2: 561-568, 1996.
7. Heidtmann HH, Salge U, Abrahamson M, Bencina M, Kastelic L, Kopitar-Jerala N, Turk V and Lah TT: Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clin Exp Metastasis 15: 368-381, 1997.
8. Mori M, Kohli A, Baker SP, Savas L and Fraire AE: Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer: are they useful? Mod Pathol 10: 572-577, 1997.
9. Krepela E, Prochazka J, Karova B, Cermak J and Roubkova H: Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer. Neoplasma 45: 318-331, 1998.
10. Nakae T, Horai T, Imamura F, Akedo H and Higashino K: Expression of cathepsin B in small cell lung carcinoma cells in relation to in vitro invasiveness. Tumour Biol 19: 118-125, 1998.
11. Fujise N, Nanashim A, Taniguchi Y, Matsuo S, Hatano K, Matsumoto Y, Tagawa Y and Ayabe H: Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer 27: 19-26, 2000.
12. Sloman A, D'Amico F and Yousem SA: Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study. Arch Pathol Lab Med 120: 465-472, 1996.
13. Werle B, Kraft C, Lah TT, Kos J, Schanzenbächer U, Kayser K, Ebert W and Spiess E: Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with non-small cell lung carcinoma. Cancer 89: 2282-2291, 2000.
14. Baumhäkel J, Kayser K, Kalman E, Kos J, Lah TT, Spiess E, Ebert W, Fiehn W and Werle B: Histological and thermodynamic features of cathepsin B-positive tumors of non-small cell lung cancer obtained by syntactic structure analysis. Elec J Pathol Histol 7: 011-06, 2001.
15. Kayser K, Kayser G, Biechele U and Gabius H-J: Ligandohistochemical, nuclear and structural analysis of primary and intrapulmonary metastatic breast carcinomas. Elec J Pathol Histol 3: 974, 1997.
16. Kayser K, Kayser G, Eichhorn S, Biechele U, Altiner M, Kaltner H, Zeng FY, Vlasova EV, Bovin NV and Gabius HJ: Association of prognosis in surgically treated lung cancer patients with cytometric, histometric and ligand histochemical properties: with an emphasis on structural entropy. Anal Quant Cytol Histol 20: 313-320, 1998.
17. Kayser G, Gunzenhäuser I, Becker HD, Herth F and Kayser K: Proliferationsrate beim kleinzelligen-anaplastischen Bronchialkarzinom-ein cytomorphologischer Parameter mit prognostischer Aussagekraft. Pathologe 23: 326-332, 2001.
18. rd edition; Berlin, Heidelberg, Springer Verlag 2000.
19. Sobin LH and Wittekind Ch (edts.): UICC: TNM Classification of Malignant Tumours. 5th edition, New York, John Wiley and Sons Inc, 1998.
20. Kayser K and Gabius, HJ: Graph theory and entropy concept. In: Graumann, L (ed), Histochemistry Progress in Histochemistry and Cytochemistry 32: Stuttgart, Jena, Lübeck, Ulm, Gustav Fischer, 1997.
21. Kayser K and Gabius H-J: The application of thermodynamic principles to histochemical and morphometric tissue research: principles and practical outline with focus on the glycosciences. Cell Tissue Res 296: 443-455, 1999.
22. Kayser K, Bovin NV, Korchgina EY, Zeilinger C, Feng F-Y and Gabius H-J: Correlation of expression of binding sites for synthetic blood group A-, B-, and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer 30A: 653-657, 1994.
23. Sukoh N, Abe S, Nakajima I, Ogura S, Isobe H, Inoue K and Kawakami Y: Immunohistochemical distributions of cathepsin B and basement membrane antigens in human lung adenocarcinoma: association with invasion and metastasis. Virchows Arch 424: 33-38, 1994.
24. Sukoh N, Abe S, Ogura S, Isobe H, Takekawa H, Inoue K and Kawakami Y: Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer 74: 46-51, 1994.
25. Werle B, Lötterle H, Schanzenbacher U, Lah TT, Kalman E, Kayser K, Bulzebruck H, Schirren J, Krasovec M, Kos J and Spiess E: Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients. Br J Cancer 81: 510-519, 1999.
26. Werle B, Staib A, Jülke B, Ebert W, Zladoisky P, Sekirnik A, Kos J and Spiess E: Fluorometric microassays for the determination of cathepsin L and cathepsin S activities in tissue extracts. Biol Chem 380: 1109-1116, 1999.
27. Szpaderska AM and Frankfater A: An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 61: 3493-3500, 2001.
28. Takeda A, Yamamoto T, Nakamura Y, Takahashi T and Hibino T: Squamous cell carcinoma antigen is a potent inhibitor of cysteine proteinase cathepsin L. FEBS Lett 359: 78-80, 1995.
29. Gerber A, Welte T, Ansorge S and Buhling F: Expression of cathepsins B and L in human lung epithelial cells is regulated by cytokines. Adv Exp Med Biol 477: 287-292, 2000.
30. Ledakis P, Tester W, Rosenberg N, Cohen M, Daskal I and Lah TT: Cathepsins D, B and L in human lung carcinoma. Clin Cancer Res 2: 561-568, 1996.